Amylin seems to be easier on the gut than GLP-1s like Ozempic, though it may produce less weight loss. advertisement. Barron's. ... kidneys and perhaps even the brain.

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin hormone receptor treatments. The hope is for less nausea and muscle loss.

Summary. AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk.